3 Coronavirus Stocks That Could Double by the End of 2020
Quite a few stocks of companies developing COVID-19 therapies and vaccines have soared this year. Is it really conceivable that the biotech stock could double over the next four months after that staggering gain? In March, the company reported very good results from a late-stage study of flu-vaccine candidate NanoFlu, which set the stage for filing for approval by the Food and Drug Administration.